Elephas Biosciences Corporation is partnering with the University of Louisville on a new research opportunity that will evaluate the impact of a combination therapy of surgical intervention and immunotherapy in…
NorthStar Medical Radioisotopes has entered into a strategic supply agreement with BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, the company announced today….
Promega is launching the TarSeer BRETSA Target Engagement System, a live-cell, target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins,…
Forward BIOLABS, in partnership with BioForward Madison, announced today the first round of awardees of the Innovation to Commercialization Pipeline (ICP) program. The awardees from the Madison area include Immuto…
Immuto Scientific and the University of Wisconsin announced recently a collaborative agreement to identify disease-specific novel therapeutic targets in colorectal cancer using Immuto’s proprietary structural surfaceomics platform. “Our work with…
FAR Biotech, a computational drug discovery company using proprietary quantum modeling and deep learning AI to tackle high-impact diseases with significant unmet medical need, announced recently that it has moved…
Immuto Scientific has entered into a research collaboration with an unnamed, U.S.-based multinational animal health company, the company announced today. According to a release, the collaboration is designed to apply…
NorthStar Medical Radioisotopes has been successful in routinely producing non-carrier-added Actinium-225 (Ac-225) using its electron accelerator-based technology, becoming the first in the industry to do so, the company announced recently….
SHINE Technologies announced recently that it acquired Lantheus’ SPECT business, which includes the SPECT manufacturing facility in Massachusetts and its portfolio of diagnostic radiopharmaceuticals. “The nuclear medicine supply chain needs…
BrainXell Therapeutics announced recently preclinical data demonstrating the efficacy of its neuronal therapy called BXT-110 as a potential disease-modifying treatment for Parkinson’s disease. BrainXell Therapeutics is using induced pluripotent stem…
